Editorial

The Role of Metformin in Diabetes Management: Efficacy and New Insights

Pankaj Shinde

Department of Quality Assurance, Bhagwan College of Pharmacy, Aurangabad, Maharashtra, India.

Correspondence:
Pankaj Shinde,
Department of Quality Assurance, Bhagwan College of Pharmacy, Aurangabad, Maharashtra, India.
E-mail: Pankaj_shinde@yahoo.com

How to cite this article: Shinde P. The Role of Metformin in Diabetes Management: Efficacy and New Insights Innov Pharm Planet (IP-Planet) 2022;10(3):41-43.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 15-07-2022
Date of Revision: 23-07-2022
Date of Acceptance: 11-08-2022

Metformin has long been a cornerstone in the treatment of type 2 diabetes mellitus (T2DM), celebrated for its effectiveness, safety profile, and affordability. Introduced in the 1950s, it remains the first-line pharmacological treatment for T2DM, prescribed to millions globally. Its ability to lower blood glucose levels and improve insulin sensitivity has cemented its status in diabetes care. However, recent studies have unveiled novel insights into its mechanisms of action, benefits beyond glycemic control, and potential limitations, warranting a renewed discussion on its role in modern diabetes management.

Efficacy and Mechanism of Action

The primary mechanism of metformin lies in reducing hepatic gluconeogenesis, effectively lowering fasting blood glucose levels. It also enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Unlike other hypoglycemic agents, metformin does not stimulate insulin secretion, minimizing the risk of hypoglycaemia. Its weight-neutral or modest weight-reducing effect adds to its appeal, particularly in patients with obesity, a common comorbidity in T2DM.

Meta-analyses confirm that metformin effectively reduces HbA1c levels by approximately 1-2%, comparable to other oral antidiabetic agents. Furthermore, its cardiovascular benefits, first highlighted in the UK Prospective Diabetes Study (UKPDS), remain a significant advantage, with evidence supporting reduced risks of myocardial infarction and all-cause mortality. [1]

Expanding Horizons: Beyond Glycemic Control

Recent research has revealed a plethora of non-glycemic benefits associated with metformin.

It has shown promise in reducing the incidence of certain cancers, such as breast, colorectal, and pancreatic cancer, attributed to its anti-inflammatory and antiproliferative effects. Additionally, its role in delaying the onset of type 2 diabetes in prediabetic individuals, as demonstrated in the Diabetes Prevention Program (DPP), underscores its preventive potential.

Emerging data suggest metformin's benefits extend to improving gut microbiota composition, modulating the immune response, and potentially slowing aging through its effects on cellular metabolism. These findings position metformin as a candidate for repurposing in non-diabetic conditions, including polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and age-related disorders. [2]

Challenges and Limitations

Despite its widespread use, metformin is not without limitations. Gastrointestinal side effects, such as diarrhea, nausea, and abdominal discomfort, are common, often leading to poor adherence. Rarely, metformin is associated with lactic acidosis, particularly in patients with significant renal impairment or hepatic dysfunction. [3]

Furthermore, its efficacy diminishes over time in many patients as beta-cell function

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275

progressively declines, necessitating the addition of other antidiabetic agents. The absence of significant glucose-lowering effects in patients with advanced diabetes underscores the need for combination therapies tailored to individual patient profiles. [4]

The pharmacogenomics of metformin is another area of growing interest. Variations in genes such as SLC22A1, encoding the organic cation transporter 1 (OCT1), influence metformin uptake and response, suggesting a potential role for personalized medicine in optimizing its use. [5]

Metformin in the Era of Novel Therapies

The advent of newer antidiabetic agents, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), has revolutionized diabetes care by offering robust glycemic control, cardiovascular benefits, and weight loss. Despite these advancements, metformin remains a foundational therapy, often prescribed in combination with newer agents to harness synergistic effects. [6]

However, questions regarding metformin's continued status as the first-line therapy in T2DM management have emerged. While its cost-effectiveness and long history of use are compelling, head-to-head trials comparing metformin with newer agents are limited. Future guidelines may need to re-evaluate metformin's position in light of evolving evidence. [7]

The Future of Metformin

As diabetes care becomes increasingly personalized, metformin's role will likely evolve. Ongoing research into its molecular mechanisms, genetic determinants of response, and long-term effects on comorbid conditions will shape its future use. Novel formulations, such as extended-release metformin and combinations with other agents, aim to improve tolerability and adherence. [8]

Moreover, exploring metformin's potential in non-diabetic populations, such as individuals at risk of cancer or aging-related conditions, represents an exciting frontier. These developments underscore the versatility of metformin and its enduring relevance in healthcare. [9]

Conclusion

Metformin's legacy in diabetes management is unparalleled, offering a potent, safe, and cost-effective option for glycemic control. Its expanding benefits beyond diabetes highlight its versatility and potential in addressing a broad spectrum of health challenges. However, as the therapeutic landscape evolves, so must our understanding of its optimal use, integrating emerging insights with clinical practice. By embracing a patient-centered approach and leveraging advancements in research, we can maximize the benefits of metformin, ensuring its continued role as a cornerstone of diabetes care.

References

1 LaMoia, T. E., & Shulman, G. I. (2021). Cellular and molecular mechanisms of metformin action. *Endocrine reviews*, *42*(1), 77-96.

2 Nyane, N. A., Tlaila, T. B., Malefane, T. G., Ndwandwe, D. E., & Owira, P. M. O. (2017). Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights. *European Journal of Pharmacology*, *803*, 103-111.

3 Lv, Z., & Guo, Y. (2020). Metformin and its benefits for various diseases. *Frontiers in endocrinology*, *11*, 191.

4 Masarwa, R., Brunetti, V. C., Aloe, S., Henderson, M., Platt, R. W., & Filion, K. B. (2021). Efficacy and safety of metformin for obesity: a systematic review. *Pediatrics*, *147*(3).

5 Kajbaf, F., Bennis, Y., Hurtel-Lemaire, A. S., Andrejak, M., & Lalau, J. D. (2016). Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. *Diabetic Medicine*, *33*(1), 105-110.

6 Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021). Should metformin remain the first-line therapy for treatment of type 2 diabetes?. *Therapeutic advances in endocrinology and metabolism*, *12*, 2042018820980225.

7 Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021). Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. *European Journal of Preventive Cardiology*, *28*(1), 69-75.

8 Thomas, I., & Gregg, B. (2017). Metformin; a review of its history and future: from lilac to longevity. *Pediatric diabetes*, *18*(1), 10-16.

9 Hostalek, U., & Campbell, I. (2021). Metformin for diabetes prevention: update of the evidence base. *Current medical research and opinion*, *37*(10), 1705-1717.